Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Target Recruit Count
- 234
- Registration Number
- NCT06148649
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China
A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects
Phase 1
Completed
- Conditions
- T2DM (Type 2 Diabetes Mellitus)ObesityHealthy Subjects
- Interventions
- Drug: HEC88473 injectionDrug: Placebo
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT05943886
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
Phase 1
Completed
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: HEC88473 injectionDrug: Placebo
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04829123
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, Australia
News
No news found